{"id":"placebo-fulvestrant","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Vaginal bleeding or discharge"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Asthenia/fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4760678","moleculeType":"Unknown","molecularWeight":"606.78"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fulvestrant works by binding to estrogen receptors (ER) with high affinity and promoting their degradation, thereby blocking estrogen signaling in hormone receptor-positive breast cancer cells. The placebo arm allows for comparison of fulvestrant's efficacy in this Phase 3 trial. This combination approach is designed to evaluate fulvestrant's therapeutic benefit in ER-positive breast cancer.","oneSentence":"Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, while placebo serves as a control arm in this combination study.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:27:36.375Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT07174336","phase":"PHASE3","title":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":920},{"nctId":"NCT04191499","phase":"PHASE2, PHASE3","title":"A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-01-29","conditions":"Breast Cancer","enrollment":325},{"nctId":"NCT07405801","phase":"PHASE2","title":"A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-03-31","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT01602380","phase":"PHASE3","title":"A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-10-17","conditions":"Hormone Receptor Positive Breast Cancer","enrollment":462},{"nctId":"NCT05038735","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-17","conditions":"Breast Cancer","enrollment":212},{"nctId":"NCT07393321","phase":"PHASE3","title":"A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","startDate":"2026-02-10","conditions":"HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer","enrollment":210},{"nctId":"NCT02763566","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2016-12-05","conditions":"Breast Cancer","enrollment":463},{"nctId":"NCT04305496","phase":"PHASE3","title":"Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-04-16","conditions":"Locally Advanced (Inoperable) or Metastatic Breast Cancer","enrollment":818},{"nctId":"NCT04650581","phase":"PHASE3","title":"Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2021-01-27","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT05169567","phase":"PHASE3","title":"Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-03-11","conditions":"Breast Neoplasm, Neoplasm Metastasis","enrollment":368},{"nctId":"NCT05860465","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2023-09-08","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":254},{"nctId":"NCT05365178","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-07-01","conditions":"HR-positive, HER2-negative Breast Neoplasms","enrollment":432},{"nctId":"NCT01992952","phase":"PHASE1, PHASE2","title":"Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Velindre NHS Trust","startDate":"2014-05-07","conditions":"Estrogen Receptor Positive Breast Cancer","enrollment":149},{"nctId":"NCT02107703","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2014-07-22","conditions":"Breast Neoplasms","enrollment":669},{"nctId":"NCT04851613","phase":"PHASE3","title":"Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Laekna Limited","startDate":"2022-02-18","conditions":"Breast Cancer","enrollment":256},{"nctId":"NCT04544189","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-01-20","conditions":"Breast Neoplasms","enrollment":69},{"nctId":"NCT00253422","phase":"PHASE3","title":"Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors","status":"COMPLETED","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2004-03-26","conditions":"Breast Cancer","enrollment":698},{"nctId":"NCT06998108","phase":"PHASE3","title":"Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy","status":"RECRUITING","sponsor":"BeBetter Med Inc","startDate":"2022-06-09","conditions":"HR+/HER2- Locally Advanced, Metastatic Breast Cancer","enrollment":330},{"nctId":"NCT06929325","phase":"PHASE3","title":"Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-04","conditions":"HR+/HER2- Advanced/Metastatic Breast Cancer","enrollment":312},{"nctId":"NCT02437318","phase":"PHASE3","title":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-07-23","conditions":"Breast Cancer","enrollment":572},{"nctId":"NCT02632045","phase":"PHASE2","title":"Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer","status":"COMPLETED","sponsor":"Melissa K Accordino","startDate":"2016-03","conditions":"Metastatic Breast Cancer, Breast Carcinoma","enrollment":169},{"nctId":"NCT04060862","phase":"PHASE1","title":"A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2019-11-21","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT05054751","phase":"PHASE3","title":"GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Genor Biopharma Co., Ltd.","startDate":"2021-09-10","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":275},{"nctId":"NCT05375461","phase":"PHASE3","title":"TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-03-18","conditions":"HR-positive,HER2-negative in Advanced Breast Cancer","enrollment":287},{"nctId":"NCT00626106","phase":"PHASE2","title":"QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"NantCell, Inc.","startDate":"2008-03-27","conditions":"Breast Cancer, Breast Tumors, Metastatic Cancer","enrollment":156},{"nctId":"NCT02964507","phase":"PHASE1","title":"Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-09-26","conditions":"Neoplasms","enrollment":124},{"nctId":"NCT02599714","phase":"PHASE1","title":"Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-12-07","conditions":"Advanced and Metastatic Breast Cancer","enrollment":54},{"nctId":"NCT05077449","phase":"PHASE3","title":"A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2021-11-16","conditions":"Advanced Breast Cancer","enrollment":300},{"nctId":"NCT01942135","phase":"PHASE3","title":"Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-09-26","conditions":"Metastatic Breast Cancer","enrollment":521},{"nctId":"NCT02422615","phase":"PHASE3","title":"Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-06-09","conditions":"Advanced Breast Cancer","enrollment":726},{"nctId":"NCT05433480","phase":"PHASE3","title":"A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2022-05-25","conditions":"Breast Cancer","enrollment":274},{"nctId":"NCT03447132","phase":"PHASE3","title":"Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant","status":"COMPLETED","sponsor":"International Cancer Research Group, United Arab Emirates","startDate":"2017-12-20","conditions":"Breast Neoplasm Female","enrollment":354},{"nctId":"NCT02340221","phase":"PHASE3","title":"A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2015-04-09","conditions":"Breast Cancer","enrollment":631},{"nctId":"NCT05438810","phase":"PHASE3","title":"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.","status":"UNKNOWN","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2022-01-18","conditions":"Advanced Breast Cancer, Female Breast Cancer","enrollment":312},{"nctId":"NCT03927456","phase":"PHASE3","title":"A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-06-13","conditions":"Advanced Breast Cancer","enrollment":357},{"nctId":"NCT00570258","phase":"PHASE2","title":"Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2006-09","conditions":"Metastatic Breast Cancer","enrollment":27},{"nctId":"NCT02137837","phase":"PHASE3","title":"S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2014-05","conditions":"Breast Cancer","enrollment":37},{"nctId":"NCT03241810","phase":"PHASE2","title":"Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Elevation Oncology","startDate":"2017-08-15","conditions":"Metastatic Breast Cancer","enrollment":22},{"nctId":"NCT01610284","phase":"PHASE3","title":"Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08-07","conditions":"Breast Cancer","enrollment":1147},{"nctId":"NCT02690480","phase":"PHASE2","title":"Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Spanish Breast Cancer Research Group","startDate":"2016-02-17","conditions":"Breast Neoplasms","enrollment":189},{"nctId":"NCT00390455","phase":"PHASE3","title":"Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-09-15","conditions":"Estrogen Receptor Positive, HER2 Positive Breast Carcinoma, HER2/Neu Negative","enrollment":295},{"nctId":"NCT00451555","phase":"PHASE2","title":"Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-04-11","conditions":"Breast Cancer","enrollment":156},{"nctId":"NCT01160718","phase":"PHASE2","title":"Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2010-08","conditions":"Breast Cancer","enrollment":46},{"nctId":"NCT01633060","phase":"PHASE3","title":"A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10-03","conditions":"Metastatic Breast Cancer","enrollment":432},{"nctId":"NCT01797120","phase":"PHASE2","title":"Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI","status":"COMPLETED","sponsor":"PrECOG, LLC.","startDate":"2013-05-31","conditions":"Metastatic Breast Cancer","enrollment":131},{"nctId":"NCT00752986","phase":"PHASE2","title":"ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2008-12","conditions":"Breast Cancer","enrollment":39},{"nctId":"NCT01437566","phase":"PHASE2","title":"Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-10","conditions":"Breast Cancer","enrollment":318},{"nctId":"NCT00454805","phase":"PHASE2","title":"AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-03","conditions":"Advanced Breast Cancer","enrollment":75},{"nctId":"NCT01528345","phase":"PHASE2","title":"Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-04","conditions":"Metastatic Breast Cancer","enrollment":97},{"nctId":"NCT02394496","phase":"PHASE3","title":"Overcoming Endocrine Resistance in Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Consorzio Oncotech","startDate":"2007-11","conditions":"Metastatic Breast Cancer","enrollment":396},{"nctId":"NCT02026973","phase":"PHASE1","title":"Impact of Endogenous E2 on SSI and GH Rebound","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-03","conditions":"Normal Healthy Volunteers","enrollment":62},{"nctId":"NCT01202591","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-12","conditions":"FGFR Inhibition, Pharmacokinetics, Biomarkers, ER+ Breast Cancer","enrollment":127},{"nctId":"NCT02530411","phase":"PHASE2","title":"Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer","status":"UNKNOWN","sponsor":"Velindre NHS Trust","startDate":"2015-04","conditions":"Neoplasms","enrollment":160},{"nctId":"NCT01300351","phase":"PHASE3","title":"Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-03","conditions":"Breast Cancer","enrollment":249},{"nctId":"NCT02115594","phase":"PHASE2","title":"Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Syndax Pharmaceuticals","startDate":"2014-04","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00811369","phase":"PHASE2","title":"Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Ontario Clinical Oncology Group (OCOG)","startDate":"2009-08","conditions":"Metastatic Breast Cancer","enrollment":126},{"nctId":"NCT00688194","phase":"PHASE3","title":"Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy","status":"UNKNOWN","sponsor":"Gruppo Italiano Mammella (GIM)","startDate":"2008-05","conditions":"Breast Cancer","enrollment":396},{"nctId":"NCT00010153","phase":"PHASE3","title":"ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2000-11","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00944918","phase":"PHASE3","title":"Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-12","conditions":"Progression-free Survival","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo + fulvestrant","genericName":"Placebo + fulvestrant","companyName":"Nanjing Chia-tai Tianqing Pharmaceutical","companyId":"nanjing-chia-tai-tianqing-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fulvestrant is being studied in combination with palbociclib and inavolisib (or placebo) for the treatment of breast cancer, metastatic breast cancer, breast tumors, and metastatic cancer. The exact mechanism of fulvestrant is unknown, but it is being used in combination with other treatments in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}